11 Although not a T2D trial, SELECT (semaglutide) enrolled patients with overweight or obesity (BMI 27 kg/m 2 ) and established CVD
GLP-1 (Glucagon-like Peptide-1) medications are a class of drugs used primarily to treat type 2 diabetes and, in some cases, to aid weight loss
According to the Stroke Association, around 152,000 strokes occur every year in the UK
The increased risk of kidney stones, on the other hand, might be less familiar
The FDA, compounding, and regulatory context Understanding the regulatory landscape around compounded semaglutide with glycine helps you make informed decisions about your treatment
Regular dental visits and proper at-home care are essential while on these medications